Download MendeleyVenglustat Inhibits Protein N-Terminal Methyltransferase 1 in a Substrate-Competitive Manner.
Dong, G., Deng, Y., Yasgar, A., Yadav, R., Talley, D., Zakharov, A.V., Jain, S., Rai, G., Noinaj, N., Simeonov, A., Huang, R.(2022) J Med Chem 65: 12334-12345
- PubMed: 36074125 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1021/acs.jmedchem.2c01050
- Primary Citation Related Structures:
7U1M - PubMed Abstract:
Venglustat is a known allosteric inhibitor for ceramide glycosyltransferase, investigated in diseases caused by lysosomal dysfunction. Here, we identified venglustat as a potent inhibitor (IC 50 = 0.42 μM) of protein N-terminal methyltransferase 1 (NTMT1) by screening 58,130 compounds. Furthermore, venglustat exhibited selectivity for NTMT1 over 36 other methyltransferases. The crystal structure of NTMT1-venglustat and inhibition mechanism revealed that venglustat competitively binds at the peptide substrate site. Meanwhile, venglustat potently inhibited protein N-terminal methylation levels in cells (IC 50 = 0.5 μM). Preliminary structure-activity relationships indicated that the quinuclidine and fluorophenyl parts of venglustat are important for NTMT1 inhibition. In summary, we confirmed that venglustat is a bona fide NTMT1 inhibitor, which would advance the study on the biological roles of NTMT1. Additionally, this is the first disclosure of NTMT1 as a new molecular target of venglustat, which would cast light on its mechanism of action to guide the clinical investigations.
- Department of Medicinal Chemistry and Molecular Pharmacology, Center for Cancer Research, Institute for Drug Discovery, Purdue University, West Lafayette, Indiana 47907, United States.
Organizational Affiliation:
